Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
January 19 2021 - 7:00AM
Business Wire
-- Research Veteran Brings More than 30
Years of Industry and NIH Experience to Kite Leadership Team
--
Kite, a Gilead Company (Nasdaq: GILD), today announced that
Francesco Marincola, MD, will join the company as Senior Vice
President and Global Head of Cell Therapy Research, effective
February 1. Dr. Marincola will lead Kite’s Research organization
across hematological malignancies and solid tumors.
“Franco’s proven track record in oncology and robust research
experience that spans the NIH to industry will be critical to the
targeting and acceleration of our research efforts in CAR T and
beyond,” said Christi Shaw, Chief Executive Officer of Kite. “As
the cell therapy leader, we are thrilled to welcome Franco to our
team and are confident that his exceptional skills and expertise
will best position our research to discover potentially life-saving
therapies for patients in need.”
Dr. Marincola joins Kite from Refuge Biotechnologies Inc., where
he was President and Chief Scientific Officer, responsible for the
development and implementation of research and clinical development
of synthetic biology strategies for adoptive cell therapy products
and lead therapeutic programs based on nuclease deactivated CRISPR
circuits. He is also a National Institutes of Health (NIH) tenured
senior investigator in cancer immunotherapy and biomarker research,
and spent 23 years at the NIH, including 15 years as the Chief of
the Infectious Disease and Immunogenetics Section at the NIH
Clinical Center. Previously, he also served as a distinguished
research fellow in immune oncology discovery at AbbVie and as Chief
Research Officer at Sidra Research in Doha, Qatar. The former
President of the Society for Immunotherapy of Cancer (SITC;
2013-2014), he currently serves as Editor-in-Chief for several
prominent peer-reviewed publications, including Journal of
Translational Medicine, Translational Medicine Communications and
Immunotherapy, and is the author of more than 600 peer-reviewed
publications.
“It is an honor to bring my experience to an industry-leading
team that is working to make cell therapies with curative intent
available to patients,” said Dr. Marincola. “I look forward to
helping build and diversify our research efforts in support of this
mission.”
About Kite
Kite, a Gilead Company, is a biopharmaceutical company based in
Santa Monica, California, with commercial manufacturing operations
in North America and Europe. Kite is engaged in the development of
innovative cancer immunotherapies. The company is focused on
chimeric antigen receptor and T cell receptor engineered cell
therapies. For more information on Kite, please visit
www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com.
For more information on Kite, please visit the
company’s website at www.kitepharma.com or call Gilead Public
Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Follow Kite on social
media on Twitter (@KitePharma) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119005084/en/
Monica Tellado, Investors (650) 219-3882
Nathan Kaiser, Media (650) 522-1853
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024